Compare · ISO vs MASI
ISO vs MASI
Side-by-side comparison of IsoPlexis Corporation (ISO) and Masimo Corporation (MASI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ISO and MASI operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- MASI is the larger of the two at $9.36B, about 39.3x ISO ($238.4M).
- MASI has hit the wire 2 times in the past 4 weeks while ISO has been quiet.
- MASI has more recent analyst coverage (24 ratings vs 7 for ISO).
- Company
- IsoPlexis Corporation
- Masimo Corporation
- Price
- $0.75+2.09%
- $178.78+0.04%
- Market cap
- $238.4M
- $9.36B
- 1M return
- -
- +0.32%
- 1Y return
- -
- +9.70%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2007
- News (4w)
- 0
- 2
- Recent ratings
- 7
- 24
IsoPlexis Corporation
IsoPlexis Corporation, a life sciences company, provides solutions for the development of curative medicines and personalized therapeutics in the United States and Europe. The company offers single cell proteomics platform, including instruments, chip consumables, and software that provides an end-to-end solution to view of protein function at an individual cellular level. It provides IsoLight and IsoSpark instruments; IsoCode chips that offer multiplexed chip solutions for single cell functional proteomics; CodePlex chips that provide multiplexed solutions for ultra-low volume bulk samples; and IsoSpeak software that offers dimensional data and automates analysis with an intuitive push button user interface to deliver same day single cell and bulk proteome visualizations without the need for highly specialized informatics professionals, as well as research support and services, and post-warranty services. The company was incorporated in 2013 and is based in Branford, Connecticut.
Masimo Corporation
Masimo Corporation develops, manufactures, and markets noninvasive monitoring technologies and hospital automation solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry. It also provides Masimo rainbow SET platform that includes rainbow SET Pulse CO-Oximetry products that noninvasively monitor hemoglobin species, including oxygen saturation, pulse rate, perfusion index, pleth variability index, and respiration rate from the pleth; noninvasively monitor hemoglobin concentration, and carboxyhemoglobin and methemoglobin; monitor arterial oxygen saturation and acoustic respiration rate; and calculates oxygen content and oxygen reserve index. The company offers SedLine brain function monitoring technology to measure the brain's electrical activity by detecting EEG signals; capnography and gas monitoring products comprising external plug-in-and-measure capnography and gas analyzers, integrated modules, handheld capnograph and capnometer devices, and capnography sampling lines; O3 regional oximetry for tissue oxygen saturation measurement; and hemodynamic monitoring solutions. Its Masimo Hospital Automation platform includes Patient SafetyNet, Patient SafetyNet surveillance, Kite, UniView, Replica, UniView : 60, and MyView. The company offers coronavirus-2019 response and telehealth solutions; connectivity devices; and nasal high flow ventilation and neuromodulation solutions. The company provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, physician offices, long term care facilities, veterinarians, and consumers; and non-medical/consumer products through e-commerce site, masimopersonalhealth.com. Incorporated in 1989, the company is headquartered in Irvine, California.
Latest ISO
- SEC Form SC 13D/A filed by IsoPlexis Corporation (Amendment)
- SEC Form 15-12G filed by IsoPlexis Corporation
- IsoPlexis Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financial Obligation, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Leadership Update, Financial Statements and Exhibits
- SEC Form S-8 POS filed by IsoPlexis Corporation
- SEC Form S-8 POS filed by IsoPlexis Corporation
- SEC Form 4 filed by Khakhar Rajesh T.
- SEC Form 4 filed by Myers Jason W.
- SEC Form 4 filed by Ho Gregory P.
- SEC Form 4 filed by Heath James R
- SEC Form 4 filed by Zhou Jing
Latest MASI
- SEC Form SD filed by Masimo Corporation
- SEC Form SCHEDULE 13G filed by Masimo Corporation
- SEC Form 10-Q filed by Masimo Corporation
- Director Scannell Timothy J converted options into 1,225 shares, increasing direct ownership by 89% to 2,608 units (SEC Form 4)
- Director Lane Wendy E converted options into 1,225 shares, increasing direct ownership by 89% to 2,608 units (SEC Form 4)
- Chairman of the Board Brennan Michelle converted options into 1,225 shares, increasing direct ownership by 17% to 8,543 units (SEC Form 4)
- Chief Human Resources Officer Hellmann Elisabeth A converted options into 335 shares and covered exercise/tax liability with 121 shares (SEC Form 4) to satisfy tax liability
- Masimo Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits
- Masimo Shareholders Approve Acquisition by Danaher
- Amendment: SEC Form 10-K/A filed by Masimo Corporation